ZA200103168B - Method of preparing delta-9-tetrahydrocannnabinol esters. - Google Patents
Method of preparing delta-9-tetrahydrocannnabinol esters. Download PDFInfo
- Publication number
- ZA200103168B ZA200103168B ZA200103168A ZA200103168A ZA200103168B ZA 200103168 B ZA200103168 B ZA 200103168B ZA 200103168 A ZA200103168 A ZA 200103168A ZA 200103168 A ZA200103168 A ZA 200103168A ZA 200103168 B ZA200103168 B ZA 200103168B
- Authority
- ZA
- South Africa
- Prior art keywords
- thc
- acid
- ether
- hexane
- silica gel
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 19
- 150000002148 esters Chemical class 0.000 title description 8
- CYQFCXCEBYINGO-UHFFFAOYSA-N THC Natural products C1=C(C)CCC2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3C21 CYQFCXCEBYINGO-UHFFFAOYSA-N 0.000 claims description 35
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 claims description 35
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical group CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 27
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical group CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 claims description 19
- FALRKNHUBBKYCC-UHFFFAOYSA-N 2-(chloromethyl)pyridine-3-carbonitrile Chemical group ClCC1=NC=CC=C1C#N FALRKNHUBBKYCC-UHFFFAOYSA-N 0.000 claims description 14
- 229940014800 succinic anhydride Drugs 0.000 claims description 14
- -1 4-amino- substituted pyridine Chemical class 0.000 claims description 11
- 239000000203 mixture Substances 0.000 claims description 7
- RGUKYNXWOWSRET-UHFFFAOYSA-N 4-pyrrolidin-1-ylpyridine Chemical group C1CCCN1C1=CC=NC=C1 RGUKYNXWOWSRET-UHFFFAOYSA-N 0.000 claims description 5
- 239000002253 acid Substances 0.000 claims description 5
- 150000001412 amines Chemical class 0.000 claims description 5
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 claims description 4
- 150000008065 acid anhydrides Chemical class 0.000 claims description 4
- 125000000217 alkyl group Chemical group 0.000 claims description 4
- 150000001875 compounds Chemical class 0.000 claims description 4
- XXGMIHXASFDFSM-UHFFFAOYSA-N Delta9-tetrahydrocannabinol Natural products CCCCCc1cc2OC(C)(C)C3CCC(=CC3c2c(O)c1O)C XXGMIHXASFDFSM-UHFFFAOYSA-N 0.000 claims description 3
- 125000002252 acyl group Chemical group 0.000 claims description 3
- 125000003277 amino group Chemical group 0.000 claims description 2
- 125000002837 carbocyclic group Chemical group 0.000 claims description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 2
- 150000004820 halides Chemical class 0.000 claims description 2
- 125000000623 heterocyclic group Chemical group 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 125000003107 substituted aryl group Chemical group 0.000 claims description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims 3
- 150000003973 alkyl amines Chemical class 0.000 claims 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 claims 1
- 230000032050 esterification Effects 0.000 claims 1
- 238000005886 esterification reaction Methods 0.000 claims 1
- 239000001384 succinic acid Substances 0.000 claims 1
- 229960004242 dronabinol Drugs 0.000 description 32
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 24
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 19
- 239000000741 silica gel Substances 0.000 description 19
- 229910002027 silica gel Inorganic materials 0.000 description 19
- ZKQFHRVKCYFVCN-UHFFFAOYSA-N ethoxyethane;hexane Chemical compound CCOCC.CCCCCC ZKQFHRVKCYFVCN-UHFFFAOYSA-N 0.000 description 18
- 239000011541 reaction mixture Substances 0.000 description 17
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 15
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 10
- 238000004128 high performance liquid chromatography Methods 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 9
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- 238000009472 formulation Methods 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 208000019695 Migraine disease Diseases 0.000 description 3
- 229930003827 cannabinoid Natural products 0.000 description 3
- 239000003557 cannabinoid Substances 0.000 description 3
- 229940065144 cannabinoids Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000002002 slurry Substances 0.000 description 3
- 241000218236 Cannabis Species 0.000 description 2
- 244000025254 Cannabis sativa Species 0.000 description 2
- 235000012766 Cannabis sativa ssp. sativa var. sativa Nutrition 0.000 description 2
- 235000012765 Cannabis sativa ssp. sativa var. spontanea Nutrition 0.000 description 2
- 208000010412 Glaucoma Diseases 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 206010027599 migraine Diseases 0.000 description 2
- 229940002612 prodrug Drugs 0.000 description 2
- 239000000651 prodrug Substances 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- YCBKSSAWEUDACY-IAGOWNOFSA-N 11-hydroxy-Delta(9)-tetrahydrocannabinol Chemical compound C1=C(CO)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 YCBKSSAWEUDACY-IAGOWNOFSA-N 0.000 description 1
- LHYQAEFVHIZFLR-UHFFFAOYSA-L 4-(4-diazonio-3-methoxyphenyl)-2-methoxybenzenediazonium;dichloride Chemical compound [Cl-].[Cl-].C1=C([N+]#N)C(OC)=CC(C=2C=C(OC)C([N+]#N)=CC=2)=C1 LHYQAEFVHIZFLR-UHFFFAOYSA-L 0.000 description 1
- YVOODUUYDJKFDY-RTBURBONSA-N 4-[[(6ar,10ar)-6,6,9-trimethyl-3-pentyl-6a,7,8,10a-tetrahydrobenzo[c]chromen-1-yl]oxy]-4-oxobutanoic acid Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(OC(=O)CCC(O)=O)=C3[C@@H]21 YVOODUUYDJKFDY-RTBURBONSA-N 0.000 description 1
- NUKYPUAOHBNCPY-UHFFFAOYSA-N 4-aminopyridine Chemical compound NC1=CC=NC=C1 NUKYPUAOHBNCPY-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- CYQFCXCEBYINGO-DLBZAZTESA-N Dronabinol Natural products C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@H]21 CYQFCXCEBYINGO-DLBZAZTESA-N 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010027603 Migraine headaches Diseases 0.000 description 1
- 208000008238 Muscle Spasticity Diseases 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical class CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 208000010399 Wasting Syndrome Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 230000001663 anti-spastic effect Effects 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 125000002843 carboxylic acid group Chemical group 0.000 description 1
- 244000261228 chanvre indien Species 0.000 description 1
- 235000005607 chanvre indien Nutrition 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 125000005265 dialkylamine group Chemical group 0.000 description 1
- IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000012259 ether extract Substances 0.000 description 1
- 229960004979 fampridine Drugs 0.000 description 1
- 238000010579 first pass effect Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000004410 intraocular pressure Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 230000007943 positive regulation of appetite Effects 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 150000003222 pyridines Chemical class 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 208000018198 spasticity Diseases 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000002511 suppository base Substances 0.000 description 1
- 125000005270 trialkylamine group Chemical group 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/78—Ring systems having three or more relevant rings
- C07D311/80—Dibenzopyrans; Hydrogenated dibenzopyrans
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrane Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pyridine Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/178,644 US6008383A (en) | 1998-10-26 | 1998-10-26 | Method of preparing delta-9-tetrahydrocannabinol esters |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200103168B true ZA200103168B (en) | 2002-07-18 |
Family
ID=22653334
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200103168A ZA200103168B (en) | 1998-10-26 | 2001-04-18 | Method of preparing delta-9-tetrahydrocannnabinol esters. |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US6008383A (fr) |
| EP (1) | EP1124817B1 (fr) |
| JP (1) | JP2002530279A (fr) |
| KR (1) | KR100711951B1 (fr) |
| CN (1) | CN1158275C (fr) |
| AT (1) | ATE279405T1 (fr) |
| AU (1) | AU770382B2 (fr) |
| BR (1) | BR9914787A (fr) |
| CA (1) | CA2348695C (fr) |
| CZ (1) | CZ20011436A3 (fr) |
| DE (1) | DE69921170T2 (fr) |
| DK (1) | DK1124817T3 (fr) |
| ES (1) | ES2232208T3 (fr) |
| GB (1) | GB2358397A (fr) |
| HU (1) | HU226777B1 (fr) |
| IL (1) | IL142668A (fr) |
| MX (1) | MXPA01004125A (fr) |
| NO (1) | NO327128B1 (fr) |
| NZ (1) | NZ511236A (fr) |
| PL (1) | PL196944B1 (fr) |
| PT (1) | PT1124817E (fr) |
| RU (1) | RU2232759C2 (fr) |
| SK (1) | SK5442001A3 (fr) |
| WO (1) | WO2000029402A1 (fr) |
| ZA (1) | ZA200103168B (fr) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6008383A (en) * | 1998-10-26 | 1999-12-28 | University Of Mississippi | Method of preparing delta-9-tetrahydrocannabinol esters |
| AU3697200A (en) * | 1999-02-04 | 2000-08-25 | New Millennium Pharmaceutical Research, Inc. | Method for enhancement of delivery of thc by the administration of its prodrugs via the nasal route |
| EP1321159A1 (fr) | 2001-12-21 | 2003-06-25 | CHIESI FARMACEUTICI S.p.A. | Dispositif d'actionnement pour inhalateur doseur pressurisé avec orifices percés par laser |
| CA2504743C (fr) * | 2002-11-12 | 2012-04-24 | Mallinckrodt Inc. | Derives cristallins d'un cannabinoide et procede de purification d'un cannabinoide |
| US20060051824A1 (en) * | 2004-09-03 | 2006-03-09 | Haoyun An | Tetrahydrocannabinoid antigens and method of use |
| US8628796B2 (en) * | 2004-12-09 | 2014-01-14 | Insys Therapeutics, Inc. | Room-temperature stable dronabinol formulations |
| CN101316832A (zh) | 2005-09-29 | 2008-12-03 | Amr科技公司 | δ-9-四氢大麻酚的生成方法 |
| AU2007281918A1 (en) * | 2006-08-04 | 2008-02-14 | Insys Therapeutics Inc. | Aqueous dronabinol formulations |
| EP2131655B1 (fr) | 2007-03-02 | 2014-05-07 | The University of Tennessee Research Foundation | Cannabinoïdes triaryl/hétéroaromatiques et leur utilisation |
| WO2009020666A1 (fr) * | 2007-08-06 | 2009-02-12 | Insys Therapeutics Inc. | Formulations liquides à usage oral de cannabinoïdes et procédés de traitement avec celles-ci |
| HUE032158T2 (en) * | 2008-10-31 | 2017-09-28 | Univ Mississippi | Process for the preparation of delta9-THC amino acid esters |
| US10239808B1 (en) | 2016-12-07 | 2019-03-26 | Canopy Holdings, LLC | Cannabis extracts |
| EP3745884A1 (fr) | 2018-01-31 | 2020-12-09 | Canopy Holdings, Llc | Poudre de chanvre |
| US11040932B2 (en) | 2018-10-10 | 2021-06-22 | Treehouse Biotech, Inc. | Synthesis of cannabigerol |
| US10569189B1 (en) * | 2019-05-17 | 2020-02-25 | NextLeaf Solutions Ltd. | Method for acetylation of cannabinoids |
| US10954209B1 (en) * | 2019-09-15 | 2021-03-23 | NextLeaf Solutions Ltd. | Acetylation of cannabinoids using sulfuric acid catalyst |
| WO2021139740A1 (fr) * | 2020-01-08 | 2021-07-15 | 成都百裕制药股份有限公司 | Dérivé tétrahydrocannabinol et son procédé de préparation et son utilisation médicale |
| IL296166A (en) | 2020-03-04 | 2022-11-01 | Pleopharma L L C | Methods and preparations for treating cannabis use disorder and facilitating cannabinoid withdrawal |
| US12029718B2 (en) | 2021-11-09 | 2024-07-09 | Cct Sciences, Llc | Process for production of essentially pure delta-9-tetrahydrocannabinol |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3728360A (en) * | 1971-08-31 | 1973-04-17 | Little Inc A | Ester derivatives of tetrahydrocannabinol |
| US4933633A (en) * | 1981-06-09 | 1990-06-12 | Adec, Inc. | Computer controlled energy monitoring system |
| US4933363A (en) * | 1988-08-16 | 1990-06-12 | Elsohly Mahmoud A | Method for effecting systemic delivery of delta-9-tetrahydrocannabinol |
| US5389375A (en) * | 1993-05-21 | 1995-02-14 | University Of Mississippi | Stable suppository formulations effecting bioavailability of Δ9 -thc |
| RU2106350C1 (ru) * | 1996-01-16 | 1998-03-10 | Научно-исследовательский институт физической и органической химии Ростовского государственного университета | Производные 8,9-дигидроксантена и способ их получения |
| US6008383A (en) * | 1998-10-26 | 1999-12-28 | University Of Mississippi | Method of preparing delta-9-tetrahydrocannabinol esters |
-
1998
- 1998-10-26 US US09/178,644 patent/US6008383A/en not_active Expired - Lifetime
-
1999
- 1999-10-26 SK SK544-2001A patent/SK5442001A3/sk unknown
- 1999-10-26 EP EP99972211A patent/EP1124817B1/fr not_active Expired - Lifetime
- 1999-10-26 RU RU2001114197/04A patent/RU2232759C2/ru not_active IP Right Cessation
- 1999-10-26 MX MXPA01004125A patent/MXPA01004125A/es not_active IP Right Cessation
- 1999-10-26 JP JP2000582389A patent/JP2002530279A/ja active Pending
- 1999-10-26 IL IL14266899A patent/IL142668A/xx not_active IP Right Cessation
- 1999-10-26 WO PCT/US1999/025141 patent/WO2000029402A1/fr not_active Ceased
- 1999-10-26 ES ES99972211T patent/ES2232208T3/es not_active Expired - Lifetime
- 1999-10-26 GB GB0109941A patent/GB2358397A/en not_active Withdrawn
- 1999-10-26 CA CA002348695A patent/CA2348695C/fr not_active Expired - Fee Related
- 1999-10-26 PL PL348118A patent/PL196944B1/pl not_active IP Right Cessation
- 1999-10-26 AU AU12349/00A patent/AU770382B2/en not_active Ceased
- 1999-10-26 DE DE69921170T patent/DE69921170T2/de not_active Expired - Fee Related
- 1999-10-26 NZ NZ511236A patent/NZ511236A/xx unknown
- 1999-10-26 HU HU0104776A patent/HU226777B1/hu not_active IP Right Cessation
- 1999-10-26 AT AT99972211T patent/ATE279405T1/de not_active IP Right Cessation
- 1999-10-26 BR BR9914787-4A patent/BR9914787A/pt not_active Application Discontinuation
- 1999-10-26 CN CNB998150606A patent/CN1158275C/zh not_active Expired - Fee Related
- 1999-10-26 DK DK99972211T patent/DK1124817T3/da active
- 1999-10-26 PT PT99972211T patent/PT1124817E/pt unknown
- 1999-10-26 CZ CZ20011436A patent/CZ20011436A3/cs unknown
- 1999-10-26 KR KR1020017005204A patent/KR100711951B1/ko not_active Expired - Fee Related
-
2001
- 2001-04-18 ZA ZA200103168A patent/ZA200103168B/en unknown
- 2001-04-23 NO NO20011999A patent/NO327128B1/no not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU770382B2 (en) | Method of preparing delta-9-tetrahydrocannabinol esters | |
| US6730519B2 (en) | Method of preparing delta-9-tetrahydrocannabinol | |
| US6365416B1 (en) | Method of preparing delta-9-tetrahydrocannabinol | |
| ES2566480T3 (es) | Métodos para purificar trans-(-)-delta9-tetrahidrocannabinol y trans-(+)-delta9-tetrahidrocannabinol | |
| JP5739344B2 (ja) | Δ−９−ｔｈｃ−アミノ酸エステルを含む組成物及び調製方法 | |
| EP1409473A2 (fr) | Conversion de cbd en $g(d)?8 -thc et en $g(d)?9 -thc | |
| EP0222413B1 (fr) | Dérivés de forskoline | |
| JPS6011037B2 (ja) | アミノジベンゾ〔ｂ，ｄ〕ピラン類の製造法 | |
| EP0587499B1 (fr) | Composés benzopyraniques, leur procédé de préparation et leur utilisation comme protecteurs cellulaires | |
| WO2021139741A1 (fr) | Dérivé cannabidiol et son procédé de préparation et son utilisation médicale | |
| NO174050B (no) | Analogifremgangsmaate for fremstilling av terapeutisk aktive benzopyranforbindelser | |
| CN115385875B (zh) | 一类紫杉醇衍生物及其制备方法和用途 | |
| EP0593697B1 (fr) | Derives de mercapto-acetamide | |
| HK1042088B (en) | Method of preparing delta-9-tetrahydrocannabinol esters | |
| KR820000122B1 (ko) | 치환된 2-비닐-크로몬의 제조방법 | |
| PL120365B1 (en) | Process for preparing novel benzocycloheptapyranes | |
| JP2002255809A (ja) | 水溶性６−クロマノールカルボン酸エステル誘導体を含む経口投与剤 |